The distributions of circulating IGFs, bioactive IGF, IGFBP‐3, and PAPP‐A, according to tertiles of IGFBP‐2 and PAPP‐A, for women with breast cancer versus controls (516 with complete IGF data), are shown in Table 2. This evidence concerns the gene IGFBP2 and breast carcinoma.